uniQure (NASDAQ:QURE) Stock Price Down 6.4% After Analyst Downgrade

Key Points

• uniQure's stock fell by 6.4% during trading, closing at $14.02 after previously trading at $14.98, reflecting a significant drop in trading volume.
• Analyst ratings are mixed, with six analysts rating the stock as buy and one as sell, indicating varying confidence levels in its future performance.
• The company recently reported a loss of $0.69 per share, outperforming analyst expectations, although it continues to show a negative net margin and return on equity.

uniQure N.V. (NASDAQ:QURE - Get Free Report) shares dropped 6.4% during mid-day trading on Tuesday after Chardan Capital lowered their price target on the stock from $38.00 to $35.00. Chardan Capital currently has a buy rating on the stock. uniQure traded as low as $14.58 and last traded at $14.02. Approximately 179,634 shares were traded during trading, a decline of 87% from the average daily volume of 1,391,692 shares. The stock had previously closed at $14.98.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a research report on Monday, May 19th. HC Wainwright restated a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Thursday, May 29th. Finally, Guggenheim reiterated a "buy" rating and set a $28.00 price target on shares of uniQure in a research note on Monday, May 12th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $36.55.

Insider Buying and Selling at uniQure

In other uniQure news, Director Jack Kaye sold 2,112 shares of the stock in a transaction on Friday, June 20th. The stock was sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director owned 20,439 shares in the company, valued at approximately $295,343.55. This represents a 9.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David D. Meek sold 2,112 shares of the firm's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $14.45, for a total value of $30,518.40. Following the completion of the transaction, the director owned 34,190 shares of the company's stock, valued at approximately $494,045.50. This represents a 5.82% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,144 shares of company stock valued at $322,426. Corporate insiders own 4.79% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in QURE. JPMorgan Chase & Co. boosted its stake in shares of uniQure by 14.7% during the fourth quarter. JPMorgan Chase & Co. now owns 453,784 shares of the biotechnology company's stock valued at $8,014,000 after acquiring an additional 58,246 shares during the last quarter. Alliancebernstein L.P. boosted its stake in uniQure by 14.2% in the 4th quarter. Alliancebernstein L.P. now owns 203,919 shares of the biotechnology company's stock worth $3,601,000 after buying an additional 25,319 shares during the last quarter. Franklin Resources Inc. boosted its stake in uniQure by 33.1% in the 4th quarter. Franklin Resources Inc. now owns 1,987,688 shares of the biotechnology company's stock worth $35,103,000 after buying an additional 494,726 shares during the last quarter. Headlands Technologies LLC acquired a new stake in uniQure in the 4th quarter worth about $326,000. Finally, Geode Capital Management LLC raised its holdings in shares of uniQure by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 520,553 shares of the biotechnology company's stock worth $9,198,000 after purchasing an additional 11,951 shares during the period. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Trading Down 1.7%

The company has a market capitalization of $751.17 million, a PE ratio of -3.49 and a beta of 0.11. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 9.98. The business has a fifty day moving average price of $14.83 and a 200 day moving average price of $13.69.

uniQure (NASDAQ:QURE - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. The company had revenue of $5.26 million for the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. Analysts expect that uniQure N.V. will post -3.75 EPS for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.